MidNite PM “Sleep Fast” And Pain Relief Claims Unsubstantiated – NAD
This article was originally published in The Tan Sheet
Executive Summary
Meda Consumer Healthcare appeals a NAD decision to the National Advertising Review Board. Meda’s evidence failed to show whether its proprietary blend or the individual ingredients provide MidNite PM’s benefits, NAD says, and stating that each ingredient has “calming properties” is “insufficient to support the claim.”
You may also be interested in...
Wink's Ad Claims For Children's Melatonin Fail In Review From J&J Challenge
NAD advises Wink Naturals to discontinue online and social media claims that its melatonin-containing supplements for children are “appropriately dosed for children” and their delivery method is superior to competing products.
In Brief
Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.